miCAR Platform Enables Simultaneous Silencing of Multiple Gene Targets Allogene to Deploy miCAR and other Technologies to Create the Next Generation of Allogeneic Cell Products SOUTH SAN FRANCISCO, Calif. and GENEVA , Jan. 11, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc.
Investigation Confirmed the Chromosomal Abnormality in a Single Patient was Not Observed in Any AlloCAR T Product and Not Related to Allogene Manufacturing Process or TALEN ® Gene Editing Clinical Trials Across the AlloCAR T Platform to Resume Pivotal Phase 2 Trial of ALLO-501A in
SOUTH SAN FRANCISCO, Calif. , Jan. 04, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that David Chang , M.D., Ph.D., President, Chief
